Clinical Trials Directory

Trials / Completed

CompletedNCT04463875

Magnesium, Vitamin B2, Feverfew, Andrographis Paniculata and Coenzyme Q10 for Episodic Migraine Prophylaxis

Real World, Open Label Prospective Experience of Supplementation With a Fixed Combination of Magnesium, Vitamin B2, Feverfew, Andrographis Paniculata and Coenzyme Q10 for Episodic Migraine Prophylaxis

Status
Completed
Phase
Study type
Observational
Enrollment
113 (actual)
Sponsor
Corfu Headache Clinic · Academic / Other
Sex
All
Age
Healthy volunteers
Accepted

Summary

To investigate efficacy and safety of a supplementation with a fixed combination of magnesium, vitamin B2, feverfew, andrographis paniculata and coenzyme Q10 (Vivinor®) in episodic migraine prevention, by an observational, prospective real-world study in 113 Greek patients with episodic migraine that were prospectively followed-up for three months. The primary endpoint was the change in monthly migraine days between baseline period (BL)and the third month of treatment (T3).

Detailed description

To investigate efficacy and safety of a supplementation with a fixed combination of magnesium, vitamin B2, feverfew, andrographis paniculata and coenzyme Q10 (Vivinor®) in episodic migraine prevention. An observational, prospective real-world study. After a one-month baseline period, Vivinor® was introduced in 113 Greek patients with episodic migraine that were prospectively followed-up for three months. The primary endpoint was the change in monthly migraine days between baseline period (BL)and the third month of treatment (T3). Secondary endpoints included changes in mean intensity of migraine and in days with use of acute migraine medications. Changes in scores of Migraine Disability Assessment questionnaire (MIDAS), Headache Impact Test-6 (HIT-6), Migraine Therapy Assessment questionnaire (MTAQ), MSQ-QOL (Migraine-Specific Quality of life questionnaire), HADS (Hospital Anxiety and Depression Scale) were also evaluated. Those with ≥50% reduction in monthly migraine days during T3 compared to BL were considered Vivinor®-responders.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTmagnesium, vitamin B2, feverfew, andrographis paniculata and coenzyme Q10Supplementation per os

Timeline

Start date
2018-04-01
Primary completion
2020-04-30
Completion
2020-05-31
First posted
2020-07-09
Last updated
2020-07-09

Locations

1 site across 1 country: Greece

Source: ClinicalTrials.gov record NCT04463875. Inclusion in this directory is not an endorsement.